Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - roxithromycin, quantity: 300 mg - tablet, film coated - excipient ingredients: glucose; propylene glycol; colloidal anhydrous silica; hyprolose; maize starch; povidone; hypromellose; magnesium stearate; titanium dioxide; purified talc - adults: roxithromycin is indicated for the treatment of the following types of mild to moderately severe infections in adults caused by or likely to be caused by susceptible microorganisms: upper respiratory tract infection: acute pharyngitis, tonsillitis, and sinusitis. lower respiratory tract infection: acute bronchitis and acute exacerbation of chronic bronchitis; community acquired pneumonia. skin and skin structure infections. nongonococcal urethritis. children: roxithromycin 150 mg tablets are indicated for the treatment of the following mild to moderately severe infections in children caused by or likely to be caused by susceptible micro-organisms: acute pharyngitis. acute tonsillitis. impetigo. appropriate culture and susceptibility tests should be performed when necessary to determine organism susceptibility and thus treatment suitability. therapy with roxithromycin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - roxithromycin, quantity: 300 mg - tablet, film coated - excipient ingredients: hyprolose; povidone; propylene glycol; purified talc; sodium starch glycollate type a; hypromellose; sodium starch glycollate type b; maize starch; magnesium stearate; colloidal anhydrous silica; poloxamer; glucose; titanium dioxide - adults: roxithromycin is indicated for the treatment of the following types of mild to moderately severe infections caused by or likely to be caused by susceptible microorganisms: upper respiratory tract infection: acute pharyngitis, tonsillitis and sinusitis. lower respiratory tract infection: acute bronchitis and acute exacerbations of chronic bronchitis; community acquired pneumonia. skin and skin structure infections. nongonococcal urethritis. appropriate culture and sensitivity tests should be performed when necessary to determine organism susceptibility and thus treatment suitability. therapy with roxithromycin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - roxithromycin, quantity: 150 mg - tablet, film coated - excipient ingredients: povidone; sodium starch glycollate type a; glucose; purified talc; hypromellose; maize starch; sodium starch glycollate type b; propylene glycol; hyprolose; poloxamer; titanium dioxide; colloidal anhydrous silica; magnesium stearate - adults: roxithromycin is indicated for the treatment of the following types of mild to moderately severe infections caused by or likely to be caused by susceptible microorganisms: upper respiratory tract infection: acute pharyngitis, tonsillitis and sinusitis. lower respiratory tract infection: acute bronchitis and acute exacerbations of chronic bronchitis; community acquired pneumonia. skin and skin structure infections. nongonococcal urethritis. children: roxithromycin 150 mg tablets are indicated for the treatment of the following mild to moderately severe infections in children caused by or likely to be caused by susceptible microorganisms: acute pharyngitis. acute tonsillitis, impetigo. appropriate culture and sensitivity tests should be performed when necessary to determine organism susceptibility and thus treatment suitability. therapy with roxithromycin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - roxithromycin, quantity: 300 mg - tablet, film coated - excipient ingredients: purified talc; hyprolose; propylene glycol; maize starch; magnesium stearate; povidone; glucose; poloxamer; titanium dioxide; hypromellose; colloidal anhydrous silica - for the treatment of mild to moderately severe infections in adults caused by or likely to be caused by susceptible micro-organisms: . acute pharyngitis, tonsillitis, sinusitis; . acute bronchitis and acute exacerbations of chronic bronchitis; community acquired pneumonia; . skin and skin structure infections; . non-gonoccocal urethritis. appropriate culture and sensitivity tests should be performed when necessary to determine organisms' susceptibility and thus treatment suitability. therapy with rulide may be initiated before results of these tests are known; once results become available, appropriate therapy should be considered.

Estats Units - anglès - NLM (National Library of Medicine)

fresenius kabi usa, llc - leucovorin calcium (unii: rpr1r4c0p4) (leucovorin - unii:q573i9dvlp) - leucovorin 200 mg in 20 ml - leucovorin calcium rescue is indicated after high dose methotrexate therapy in osteosarcoma.   leucovorin calcium is also indicated to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosages of folic acid antagonists. leucovorin calcium is indicated in the treatment of megaloblastic anemias due to folic acid deficiency when oral therapy is not feasible. leucovorin is also indicated for use in combination with 5-fluorouracil to prolong survival in the palliative treatment of patients with advanced colorectal cancer. leucovorin should not be mixed in the same infusion as 5-fluorouracil because a precipitate may form. leucovorin is improper therapy for pernicious anemia and other megaloblastic anemias secondary to the lack of vitamin b12 . a hematologic remission may occur while neurologic manifestations continue to progress.

Irlanda - anglès - HPRA (Health Products Regulatory Authority)

blue bio pharmaceuticals ltd - glucosamine sulfate - film-coated tablet - 1500 milligram(s) - other antiinflammatory and antirheumatic agents, non-steroids; glucosamine

Irlanda - anglès - HPRA (Health Products Regulatory Authority)

laboratoires expanscience - glucosamine - tablet - 625 milligram(s) - other antiinflammatory and antirheumatic agents, non-steroids; glucosamine

Armènia - anglès - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

ibn al-haytham pharma industries co. - glucosamine (glucosamine hydrochloride), chondroitin sulfate (chondroitin sulfate sodium) - tablets film-coated - 500mg+400mg

Armènia - anglès - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

ibn al-haytham pharma industries co. - glucosamine (glucosamine hydrochloride), chondroitin sulfate (chondroitin sulfate sodium) - tablets film-coated - 500mg+ 400mg

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

blackmores ltd - glucosamine sulfate sodium chloride, quantity: 628 mg (equivalent: glucosamine sulfate, qty 500 mg) - tablet, film coated - excipient ingredients: calcium hydrogen phosphate dihydrate; microcrystalline cellulose; croscarmellose sodium; hydrogenated vegetable oil; hypromellose; colloidal anhydrous silica; magnesium stearate; carnauba wax; sodium; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3000; lecithin